GA-INSPIRE-BRANDS
17.1.2024 14:01:31 CET | Business Wire | Press release
Today, Inspire Brands announced two international franchise agreements to bring Jimmy John’s, the largest owned-delivery sandwich brand in the United States, to Canada and Latin America, launching the brand’s global expansion plan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240117651076/en/
Jimmy John's international store concept design (Photo: Business Wire)
Jimmy John's focus on quality ingredients, convenience and digital innovation blended with ease of operations uniquely positions the brand for international appeal. Its global expansion will usher in a new way for international guests to enjoy its iconic menu—the ability to order hot, toasted sandwiches as a customization option.
"For 40 years, Jimmy John's has taken a straightforward approach to making ridiculously good, quality sandwiches and it's now time to share them with the world," said Michael Haley, President & Managing Director, International for Inspire Brands. “In a global restaurant environment where simplicity is paramount, we're confident this brand is primed for extensive international growth."
Jimmy John’s has reached agreements with two strong operators who both possess significant quick service restaurant experience and have established extensive footprints throughout Canada and Latin America.
- Foodtastic - A leading franchisor of restaurant brands in Canada, with more than 1,100 restaurants and $1.1 billion in sales.
- Franquicias Internacionales - Based in El Salvador, has a robust portfolio of several complementary businesses across food and beverage, digital media and logistics.
Jimmy John’s obsessive approach to culinary excellence and operational efficiency has helped fuel its growth in the U.S. and will be the foundation of the brand’s international expansion.
Quality Obsessed:
- Bread baked fresh in the restaurant throughout the day
- Premium meats and cheeses, as well as fresh vegetables that are hand-sliced in restaurants daily
Convenience Obsessed:
- Sandwiches, customized to your liking, made fresh and fast right when you want them
- Speedy accessibility via drive-thru, pick-up, and delivery
Technology Obsessed:
- Industry-leading mobile app and online ordering enabled through POS integration
- Exclusive rewards through the international loyalty program
While Jimmy John's is just embarking on its global journey, Inspire Brands is no stranger to international expansion. As a multi-brand restaurant company with more than 32,000 locations worldwide, including Arby's®, Baskin-Robbins®, Buffalo Wild Wings®, Dunkin'®, Jimmy John's® and SONIC®, Inspire has a robust international presence, with more than 9,900 locations.
Jimmy John's global expansion will be supported by Inspire's extensible, shared services platform and its international team, which has a wealth of experience managing and operating brands globally.
To learn more about growth opportunities with Jimmy John’s and Inspire, please visit inspirebrands.com/franchising/international/.
About Inspire Brands
Inspire Brands is a multi-brand restaurant company whose portfolio includes more than 32,000 Arby’s, Baskin-Robbins, Buffalo Wild Wings, Dunkin’, Jimmy John’s, and SONIC locations worldwide. The company was founded in 2018 and is headquartered in Atlanta, Georgia. For more information, visit InspireBrands.com.
About Jimmy John’s
Jimmy John’s, founded in 1983, is the largest owned delivery sandwich brand in the United States, with more than 2,600 restaurants in 48 states. Jimmy John’s is part of the Inspire Brands family of restaurants. For more information, visit JimmyJohns.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117651076/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom